Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Hydrazinecarboxamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 3/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | MAOA | P21397 | 1/20 | 0.67 |
| ▸ | THPO | P40225 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 5/20 | 0.62 |
| ▸ | BLM | P54132 | 4/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA5A | P35218 | 3/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.35 |
| ▸ | NT5E | P21589 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrazinecarboxamide SCHEMBL825388 | 0.90 | TSHR (0.71) | TSHRNFKB1CYP1A2MAOAMAOB | |
| Hydrazinecarboxamide SCHEMBL7615707 | 0.90 | TSHR (0.71) | TSHRNFKB1CYP1A2MAOAMAOB | |
| Hydrazinecarboxamide SCHEMBL9797148 | 0.87 | LMNA (0.73) | TSHRNFKB1CYP1A2MAOAMAOB | |
| Hydrazinecarboxamide SCHEMBL28328714 | 0.87 | LMNA (0.73) | TSHRNFKB1CYP1A2MAOAMAOB | |
| Hydrazinecarboxamide SCHEMBL27857387 | 0.84 | TSHR (0.62) | TSHRNFKB1CYP1A2MAOAMAOB | |
| Hydrazinecarboxamide SCHEMBL27857386 | 0.84 | TSHR (0.62) | TSHRNFKB1CYP1A2MAOAMAOB | |
| Urea SCHEMBL2959932 | 0.82 | — | — | |
| Hydrazinecarboxamide SCHEMBL5075202 | 0.82 | TSHR (0.83) | TSHRNFKB1CYP1A2MAOAMAOB | |
| Urea SCHEMBL28006959 | 0.82 | LMNA (0.50) | TSHRNFKB1CYP1A2MAOAMAOB | |
| Hydrazinecarboxamide SCHEMBL18613867 | 0.82 | TSHR (1.00) | TSHRNFKB1CYP1A2MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7235671-B2 | Process for preparing 3-chloromethyl-1,2,4-triazolin-5-one | MERCK & CO. INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-20060052355-A1 | reacting a chloro contaiing triaryl- or trialkyl-orthoester with a sulfonic acid salt of semicarbazide in an organic solvent, adding a brine solution to the concentrated reaction mixture,cooling the mixture to form a solid product, acidification with aqueous acid | MERCK SHARP & DOHME CORP. | 2006-03-09 | — | — | US | disclosed |
| EP-1549623-A4 | PROCESS FOR PREPARING 3-CHLOROMETHYL-1,2,4-TRIAZOLIN-5-ONE | MERCK & CO INC (US) | 2005-10-05 | — | — | EP | disclosed |
| EP-1549623-A2 | PROCESS FOR PREPARING 3-CHLOROMETHYL-1,2,4-TRIAZOLIN-5-ONE | Merck & Co., Inc. (US) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004017898-A2 | PROCESS FOR PREPARING 3-CHLOROMETHYL-1,2,4-TRIAZOLIN-5-ONE | MERCK & CO., INC. (US) | 2004-03-04 | — | — | WO | disclosed |
| EP-0789570-A4 | ORAL HYPOGLYCEMIC AGENTS | LILLY CO ELI (US) | 1998-09-30 | — | — | EP | disclosed |
| EP-0789570-A1 | ORAL HYPOGLYCEMIC AGENTS | ELI LILLY AND COMPANY (US) | 1997-08-20 | — | — | EP | disclosed |
| US-5641796-A | PHENYL-OXAZOLYL-ALKYLOXY OR THIO-PHENYLALKYL TRIAZOLINE-3-ONE OR THIONE ANTIDIABETIC AGENT | ELI LILLY AND COMPANY (US) | 1997-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052355-A1 | reacting a chloro contaiing triaryl- or trialkyl-orthoester with a sulfonic acid salt of semicarbazide in an organic solvent, adding a brine solution to the concentrated reaction mixture,cooling the mixture to form a solid product, acidification with aqueous acid | CLIC1, CTRC, NISCH | MAOB 554/4885TSHR 967/4885NFKB1 2444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.